Oral cabozantinib capsules, a tyrosine kinase inhibitor, indicated for progressive, metastatic medullary thyroid carcinoma. Supplied to endocrinology and oncology practices, tertiary hospitals, and through specialty pharmacies for ongoing patient management in advanced cancer care.